High Dose Infliximab in the Treatment of Refractory Uveitis: Does Dose Matter?

High Dose Infliximab in the Treatment of Refractory Uveitis: Does Dose Matter?

Background. Infliximab (INF) has been shown to be beneficial in treating refractory uveitis, however, no data exist on optimal dosing and the efficacy of higher dosing. Objectives. To compare the efficacy of low-dose (LD) (<10 mg/kg), moderate-dose (MD) (≥10-15 mg/kg), and high-dose (HD) INF (≥15-20 mg/kg) in the treatment of uveitis. Methods. Retrospective chart review children with uveitis di...

Infliximab in the treatment of refractory uveitis. Does dose really matter?

Methods We conducted a retrospective study at Children’s Hospital Los Angeles and Miller Children’s Hospital, Los Angeles. We performed comprehensive medical record review to identify demographic information and clinical data. Ocular outcome was assessed by anterior chamber cell density, flare, visual acuity, intra ocular pressure and ability to reduce or stop concomitant topical or systemic st...

Infliximab for Refractory Noninfectious Uveitis

Kruh et al. set out to establish whether infliximab is safe and effective for the treatment of refractory noninfectious uveitis. They found that the drug—a monoclonal antibody used in treating several chronic inflammatory diseases—induced a high rate of complete clinical remission in recalcitrant uveitis and was well tolerated by most patients. In this retrospective, interventional, noncomparat...

Tolerability of high-dose aripiprazole in treatment-refractory schizophrenic patients.

High-dose intravenous azathioprine pulse treatment in refractory Wegener's granulomatosis.

SIR, in Wegener’s granulomatosis (WG) standard therapy with cyclophosphamide (CYC) is limited by treatment-associated shortand long-term morbidity and mortality as well as insufficient response in about 10% of all cases [1]. Several therapeutic regimes have been used for refractory disease with varied results, including monoclonal antibodies to TNF[2] and different surface markers of T-cells (C...